Cluster-Randomized Trial of Air Filtration and Ventilation to Reduce Covid19 Spread in Homes

Sponsor
Stanford University (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05777720
Collaborator
(none)
200
2
2
16
100
6.2

Study Details

Study Description

Brief Summary

Investigators are evaluating whether an intervention consisting of box-fans with MERV 16 filters ("filtration fans") and recommendations for improving ventilation in the home can reduce secondary spread of Covid19 from an index case to susceptible contacts within the home.

Condition or Disease Intervention/Treatment Phase
  • Device: Filtration Fan
  • Behavioral: Safe-home pamphlet
  • Behavioral: Mid-week phone call
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
A Cluster-randomized Controlled Trial of Air Filtration and Ventilation Improvements to Reduce SARS CoV 2 Transmission Among Household Contacts
Actual Study Start Date :
Jan 30, 2023
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Jun 1, 2024

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Control

No intervention will be administered in this arm. Investigators will give families a CO2 monitor to measure average CO2 levels in the home. Investigators will provide a link to the basic CDC isolation guidelines which would be part of standard of care. Investigators will test family members at day 0-1 for baseline testing; and again on day 7 for assessing secondary transmission among susceptible contacts.

Experimental: Intervention

Families are provided with one filtration fan unit per room in their home (and one for the index case; if the family lives in a studio, they would receive 2 units). Investigators will advise families on ventilation improvements in their home. Investigators will provide an instructional pamphlet that describes how the fans work and the importance of ventilation. Investigators will follow-up on day 3-4 to check in and run through a checklist to ensure the fans are working and ventilation improvements are being attempted. Investigators will give families a CO2 monitor to measure average CO2 levels in the home. Investigators will test family members at day 0-1 for baseline testing; and again on day 7 for assessing secondary transmission among susceptible contacts.

Device: Filtration Fan
Investigators are using box fans with attached MERV16 filters, a design that has been tested and published in the scientific literature.

Behavioral: Safe-home pamphlet
The pamphlet has information on how the filtration fans work through visual images; and images of ventilation improvements in the home through opening windows.

Behavioral: Mid-week phone call
On day 3-4 of the study, the study coordinator assigned to the house will call and check in regarding the filtration fan usage and remind families about the importance of filtration and ventilation.

Outcome Measures

Primary Outcome Measures

  1. Incidence of Covid19 [7th day since enrollment in the trial]

    Investigators will measure the incidence of Covid19 in susceptible contacts on day 7.

Secondary Outcome Measures

  1. Incidence of new upper respiratory symptoms [7th day since enrollment in the trial]

    Investigators will measure reported new upper respiratory symptoms in susceptible contacts.

  2. Average CO2 levels [7 days]

    Investigators will measure 7 day average CO2 levels in the home (measured in parts per million)

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Household members live in a shared space (apartment, home) with others (as opposed to renting single rooms in a shared space, for example)

  • At least 3 other people live in the household aside from index case

Exclusion Criteria:
  • If index case test positive day was over 2 days prior

  • If half or more household members are thought to be infected already

  • If household has fewer than 3 contacts interested in participating in the study

  • If fewer than 3 contacts are expected to be present in the house for a majority of the following 7 days

Contacts and Locations

Locations

Site City State Country Postal Code
1 San Mateo Medical Center San Mateo California United States 94403
2 Stanford University Medical Center Stanford California United States 94305

Sponsors and Collaborators

  • Stanford University

Investigators

  • Study Director: Yvonne Maldonado, MD, Stanford University
  • Principal Investigator: Abraar Karan, MD, Stanford University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Abraar Karan, Post-Doctoral Fellow, Stanford University
ClinicalTrials.gov Identifier:
NCT05777720
Other Study ID Numbers:
  • 55479
First Posted:
Mar 21, 2023
Last Update Posted:
Mar 21, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Abraar Karan, Post-Doctoral Fellow, Stanford University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 21, 2023